CLINICAL_TRIALS
trial_result
· 2024-12-05
Clinical Trial Update: Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease [Phase 3]
Summary
A Phase 3 induction study evaluating oral ozanimod for moderately to severely active Crohn's disease has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-12-05